

Dinah Sah, Senior Vice President of Neuroscience and Rob Kotin, Vice President of Production Honored Among PharmaVOICE 100 Most Inspiring People

August 1, 2014 3:06 PM ET

Cambridge, Mass., August 1, 2014 – [Voyager Therapeutics](#), a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), is proud to announce that Senior Vice President of Neuroscience, Dinah Sah, Ph.D., and Vice President of Production, Rob Kotin, Ph.D., were each selected for inclusion in [PharmaVOICE's 100 most inspiring people](#).

“Dinah and Rob have a passion for innovative approaches to help develop breakthrough treatments that inspire not only the Voyager team, but the entire industry,” said Steve Paul, M.D., Voyager’s Interim President of R&D and Venture Partner at Third Rock Ventures. “Their exemplary leadership and extensive expertise are going to be instrumental in the future success of Voyager, which strives to translate the potential of gene therapy into innovative and much needed treatments for patients.”

Dr. Sah is a thought leader in the field of neuroscience and has 20 years of experience in biotechnology research and development across multiple therapeutic areas. Prior to Voyager, she played a pioneering role in the development of a new class of drugs based on RNA interference. At Voyager, Dr. Sah is responsible for the company’s preclinical neuroscience efforts, and she has been instrumental in driving the selection and advancement of Voyager’s lead product programs. Dr. Sah epitomizes Voyager's shared goal of developing breakthrough treatments for patients with serious CNS disorders that have few, if any, currently available treatment options. Dr. Sah received a B.S. in biology from the Massachusetts Institute of Technology, a Ph.D. in neurobiology from Harvard University and completed her post-doctoral training at Harvard Medical School.

Dr. Kotin established himself as a leader and innovator in adeno-associated virus (AAV) biology in academia and is rapidly translating his expertise to Voyager’s operations. Prior to Voyager, Dr. Kotin was a Senior Investigator and Laboratory Chief at the National Institutes of Health, where he had been based for close to 20 years. He has been a pioneer in multiple facets of AAV gene therapy, including the development of a novel baculovirus-based rAAV production system. This production system is used to generate the only currently approved gene therapy product in the U.S. or Europe. As a key member of the Voyager leadership team, Dr. Kotin is leading a number of key strategic activities within the company, including process R&D and production. Dr. Kotin holds a B.A. in biology from the University of California, Santa Cruz and a Ph.D. in microbiology from Rutgers University and the University of Medicine and Dentistry of New Jersey.

Established 10 years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. The PharmaVOICE 100 are selected based upon nominations submitted by colleagues and peers describing how the nominees have inspired, motivated, and affected positive change within their organizations, as well as other factors, such as community and philanthropic activities. The PharmaVOICE 100 represents a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trials, research and development, patient education, patient recruitment, advertising, technology and many others.

About Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is

headquartered in Cambridge, Mass. For more information, please visit www.voyagertherapeutics.com.

About PharmaVOICE

PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE reaches more than 17,500 readers every month in print and 70,000 with its digital edition.

PharmaVOICE's unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships.

###

Media Contact:

Katie Engleman
Pure Communications, Inc.

910-509-3977